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Abstract
COX20/FAM36A encodes a mitochondrial complex IV assembly factor impor-
tant for COX2 activation. Only one homozygous COX20 missense mutation has
been previously described in two separate consanguineous families. We report
four subjects with features that include childhood hypotonia, areflexia, ataxia,
dysarthria, dystonia, and sensory neuropathy. Exome sequencing in all four
subjects identified the same novel COX20 variants. One variant affected the
splice donor site of intron-one (c.41A>G), while the other variant
(c.157+3G>C) affected the splice donor site of intron-two. cDNA and protein
analysis indicated that no full-length cDNA or protein was generated. These
subjects expand the phenotype associated with COX20 deficiency.
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Introduction
COX20 (also known as FAM36A; MIM#614698) encodes
a protein with a role in the assembly and stability of
mitochondrial complex IV (CIV).1,2 Complex IV is the
final component of the respiratory chain and is respon-
sible for the reduction of molecular oxygen and oxida-
tion of cytochrome C. Several disorders have been
associated with mutations of both nuclear- and mito-
chondrial-encoded proteins that cause CIV deficiency,
and have presented with encephalopathies, myopathies,
and metabolic acidoses.3–7 Previous work indicated that
COX20 is important for CIV function since COX20-defi-
cient mitochondria accumulated respiratory chain assem-
bly intermediates and showed reduced respiratory
capacity.2,8 This dysfunction was linked to COX20’s role
in the maturation of the COX2 protein and COX2’s
integration into the CIV holocomplex.8
Two previous reports identified a rare neurological
disorder associated with COX20 deficiency.2,9 Three sub-
jects from two separate consanguineous Turkish families
were found to possess the same homozygous COX20
mutation (c.154A>C; p.T52P) and presented with hypo-
tonia, dystonia, dysarthria, ataxia, and sensory neuropa-
thy.1,9 One family had a child with additional findings
of microcephaly, mildly elevated serum and CSF lactate,
and a normal brain MRI.1 The other family had two
siblings, a 32-year-old sister and 25-year-old brother,
with childhood-onset of symptoms along with cerebellar
atrophy and sensory neuropathy.9 Analysis of muscle
biopsies from all subjects showed decreased CIV activity.
Protein analysis of fibroblasts revealed an absence of
COX20 protein.1,9 Analysis of fibroblast mRNA indicated
the shared missense variant was also associated with
decreased expression of the full-length mRNA and
increased expression of a splice variant that excluded
exon 2 (DEXON2).9
We describe four additional subjects with a COX20-
related neurological disorder with features that included
childhood hypotonia, areflexia, ataxia, dysarthria, dysto-
nia, and sensory neuropathy. Exome sequencing identi-
fied the same novel COX20 variants in all four subjects,
which included a splice site variant (c.157+3G>C) on
one allele, while the other allele possessed two separate
variants (c.41A>G; p.K14R and c.340G>A; p.G114S).
mRNA and protein analysis in fibroblasts showed an
absence of full-length mRNA and COX20 protein. Fur-
ther analysis revealed this was the result of the
c.157+3G>C splice donor site variant affecting the splic-
ing of exon two and the c.41A>G variant affecting the
splicing of exon one.
Materials and Methods
Protocol, patients, and consents
Protocols were approved through the National Human
Genome Research Institute and Cedars-Sinai Medical
Center (CSMC) institutional review boards (Protocols 76-
HG-0238 and Pro00037131, respectively) and the families
gave informed consent. The patients were evaluated at the
University of Iowa Stead Family Children’s Hospital, East-
ern Health in Newfoundland, Canada, CSMC and at the
NIH Clinical Center through the NIH Undiagnosed
Diseases Program.10,11
Exome sequencing
Exome sequencing was performed on family trios as per
previous protocols and the identified genetic variants were
evaluated and classified according to published guidelines
(GeneDx, Gaithersburg, MD).12,13
Cell culture and expression analysis
More detailed information can be found in
Appendix S1. Subject-1’s fibroblasts were grown at 37°C
under 5% CO2 in Dulbecco’s Modified Eagles Medium
(Thermo Fisher Scientific, Waltham, MA) supplemented
with 10% bovine serum and 1% of penicillin/strepto-
mycin (Thermo Fischer Scientific). RNA was extracted
from cells and reversed transcribed into cDNA. Tran-
scripts were amplified with primers localizing to exons 1
or 4, separated on an agarose-gel, and quantified with
ImageJ (NIH, Bethesda, MD). Western blots of protein
extracts were transferred to a membrane and incubated
with primary and secondary antibodies and quantified
with ImageJ.
Results
Subject-1
Thirteen-year-old female with infantile hypotonia who
walked at 14 months and developed progressive ataxia
associated with areflexia and dysmetria at 23 months. At
5 years, she developed a stuttering dysarthria and episodic
dystonia. Her gait progressively worsened and she became
nonambulatory at 7 years. She has continued with age-
appropriate schoolwork.
Nerve conduction studies at 13 years demonstrated a
marked sensory neuropathy. The right median sensory
nerve action potentials (SNAPs) had severely decreased
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amplitude of 3 lV (normal >20 lV). The right ulnar,
sural, and radial SNAPs could not be elicited; in contrast,
her motor studies were normal. MRI of the brain at 23
months, 6 years, and 12 years were normal. Spinal MRI
at 12 years reported that the spinal cord that was “thinner
than normal, particularly in the thoracic region”
(Fig. S1). At 5 years, cerebrospinal fluid analysis showed a
normal basic profile and neurotransmitter metabolites.
Serum evaluation for neuropathy was normal. At 7 years,
mitochondrial respiratory chain enzyme analysis of her
fibroblasts was normal (this is not uncommon with
mitochondrial fibroblast studies)14,15 (Baylor Genetics,
Houston, TX).
On examination at 12 years, she was awake, alert,
and followed commands. Cognition was normal. She
was dysarthric with a staccato whispering quality and a
pronounced stammer. Her receptive language was
unimpaired. Naming and repetition were normal. She
had oculomotor apraxia and disruption of her smooth
pursuits, otherwise her cranial nerves were normal. She
had increased tone in her lower extremities and con-
tractures at the knees. She had truncal weakness and
was unable to sit unsupported. She had decreased
strength at the hips and knees and ankles. Her left foot
had a pes cavus deformity. She was areflexic and had
extensor plantar responses bilaterally. Significant dysme-
tria and dysdiadochokinesia were present. She had dys-
tonic posturing of both hands during her attempts to
walk. These movements involved the twisting and
clenching of her hands. She also had dystonic posturing
of both feet with inversion and in toeing. Her right
side was more affected by these movements than the
left. Her gait was significant for some toe walking asso-
ciated with spasticity.
Subject-2
Thirty-two-year-old female is the sister of Subject-3. She
was without developmental concerns until age 2 years
when she was felt to become “clumsy”. Strabismus was
present at 3 years. She then developed progressive ataxia
(truncal, then appendicular) and dysarthria. By age 7, she
was areflexic and unable to climb stairs safely due to
unsteadiness. At 10 years, she started using a walker. She
was also treated for attention-deficit hyperactivity syn-
drome (ADHD), but did well in regular classes. She
developed bilateral foot drop at age 11 years. She required
increasing assistance at school. At age 16, she had increas-
ing frequency of falls and exam started to show mildly
increased tone in the legs with upgoing toes. She reported
normal sensation to all modalities on exam. At 17 years,
she started having episodic dystonic posturing of her feet,
which did not respond to carbidopa/levodopa treatment.
During this period, she developed depression, which
responded to Selective Serotonin Reuptake Inhibitor
treatment; however, she developed more significant psy-
chiatric issues that required antipsychotic medication.
Formal neuropsychological testing at 18 yo showed low-
average overall cognitive functioning. She became nonam-
bulatory and developed incontinence at 19 years. Cogni-
tive and social skills continued to decline. In her 20s, she
developed painful muscle spasms that were treated with
baclofen. Through her 20s, her condition stabilized with
significant disability.
Normal diagnostic testing included several MRIs of
brain and an MRI of the spine at 19 years. Nerve conduc-
tion studies at 6 years had absent sensory action poten-
tials in the left median and ulnar nerves and very low
amplitude in the left sural nerve consistent with a sensory
neuropathy.
At examination at 31 years, she had significant psy-
chomotor retardation, perseverative speech, dysarthria,
and was nonambulatory. She had increased tone
throughout. Her legs were held in tonic extension with
inversion of feet. She had dysmetria with arm move-
ments. She was areflexic. Sensation testing was not
reliable.
Subject-3
Twenty-eight year-old brother of Subject-2 that was
always more severely affected than his sister. He had
infantile hypotonia, and early milestones were delayed
with him starting to walk at 17 months and started
speaking around 2 years. He had progressive ataxia (trun-
cal, then appendicular) and dysarthria. He had mild cog-
nitive disability and required special education
throughout his schooling. At 10 years, he developed bilat-
eral foot drop and ataxia, but was still ambulating with a
walker. Sensation could not be tested accurately. At
13 years, he was using a wheelchair and soon started hav-
ing inverted dystonic posturing of his feet. His dystonia
progressed to involve his upper and lower extremities. He
also developed frequent choreiform movements. His tone
became progressively increased at this time. Cognitive
function remained stable, although in young adulthood
he developed some variable symptoms of depression.
At 3 years, he had a very limited electromyography and
nerve conduction study that was read as normal. He has
never had an MRI of the brain or spine.
Examination at 28 years showed limited voluntary
speech with appropriate content that was accompanied
by moderate to severe dysarthria. He was nonambula-
tory, was hypertonic throughout with frequent dystonic
posturing of his hands. Deep tendon reflexes were
absent.
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Subject-4
Seven-year-old male with childhood hypotonia who met
normal language and motor milestones until 18 months
when he developed a progressive wide-based gait associ-
ated with bilateral ankle pronation and frequent falls. At
5 years, he started having slurred dysarthric speech and
longer walks became more difficult. His gait progressively
worsened and he became nonambulatory at 7 years. He
recently developed issues with bowel and bladder control.
His speech has also continued to worsen. He is noted to
have some mild cognitive disability and attention-deficit
hyperactivity disorder, although he has continued with
age-appropriate schoolwork. Family notes he has a “high
pain threshold” and will have blisters on his feet that do
not concern him. He currently has not developed any
dystonic movements.
Nerve conduction studies at 5 years demonstrated a
sensory neuropathy with absent left ulnar, median, and
sural SNAPs; motor studies were normal. MRI of the
brain (5 and 6 years) and spine (6 years) and EEG were
also normal. Other genetic testing was unrevealing (see
Appendix S1).
On examination at 7 years, he had mild hypotonia, liga-
mentous laxity, hyperextension of knees, and calcaneal val-
gus deformities of feet. He has numerous dental caries and
hypomineralized teeth. Ophthalmological exam showed
some limitation of his smooth pursuits. He was alert and
interactive. His speech was slow without a scanning qual-
ity. He had appendicular hypotonia, but good strength.
He had significant dysmetria and ataxia. He had a wide-
based gait with bilateral ankle pronation. He was areflexic.
He had a normal temperature and vibration testing.
None of the subjects have had any history of seizures,
migraines, head trauma, or meningitis. None of them
have any family history of similar presentations, ataxia,
dystonia, or sensory neuropathy.
Exome sequencing
Exome sequencing revealed three novel compound
heterozygous variants in the COX20 gene in all four sub-
jects. One allele possessed a variant (c.157+3G>C) involv-
ing the splice donor site of intron 2 (IVS2; Fig. 1). The
other allele possessed two missense variants. One variant
(c.340G>A, p.G114S) involved an amino acid substitution
near the C-terminus that has not been conserved across
species and so was believed to be benign. The other vari-
ant consisted of a conservative amino acid substitution
(c.41A>G, p.K14R), but its proximity to the splice donor
site of intron-1 (IVS1) indicated a splicing defect could
also be playing a role (Fig. 1).
Figure 1. Pedigrees and COX20 mutations. (A) Family pedigrees. Affected individuals are indicated in black. From left to right: Subject-1 family
pedigree, Subject-2 and Subject-3 family pedigree, and Subject-4 family pedigree (B) Protein homology across species. The p.K14 and p.T52
residues are conserved across species; however, the C-terminal p.G114 residue is not.
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Expression analysis
Similar to a previous report,9 control fibroblasts possessed
two distinct transcripts, a full-length transcript and
another consistent with a DEXON2 transcript. In Subject-
1’s fibroblasts, only the noncoding transcript was
detected, with no full-length transcript being expressed.
Consistent with this finding, protein analysis revealed no
detectable COX20 protein present (Fig. 2).
Discussion
COX20 is a nuclear-encoded assembly factor that is
important for mitochondrial complex IV function.1
COX20 deficiency is a rare recessive mitochondrial disor-
der associated with a unique phenotype that includes
early-onset hypotonia, ataxia, areflexia, dystonia, dysar-
thria, and sensory neuropathy. Three affected children
were previously reported from two separate consan-
guineous Turkish families, all with the same homozygous
pathogenic mutation (c.154A>C; p.T52P).1,9 This
substitution was initially reported to decrease expression
of COX20 and reduce the levels of associated CIV pro-
teins and activity.1 Further analysis indicated that altered
splicing of intron 2 due to the variant’s proximity to the
splice donor site also played a role. This alteration caused
a reduction in full-length mRNA and an increase in the
amount of an alternatively spliced DEXON2 mRNA,
which when combined with any altered protein function
of the T52P substitution led to the decrease in COX20
activity.9
All four of our subjects presented with the same novel
compound heterozygous COX20 mutations that also
altered mRNA splicing and protein expression. One vari-
ant (IVS2+3G>C), located near intron-2’s splice donor
site, resulted in increased expression of the DEXON2
mRNA. Two linked missense variants were also identified.
The G114S substitution was near the C-terminal end of
the protein and was at a residue that is not conserved
among mammals. This likely had little or no effect on
any expressed protein. Alternatively, the K14R substitu-
tion occurred at a residue that is conserved in mammals;
Figure 2. Gene, mRNA, and protein analysis (A) COX20 gene and mRNA schematic. The gene schematic indicates the location of COX20
mutations. The previously reported c.154A>C; p.T52P is shown, along with c.157+3G>C intron 2 splice site mutation and missense mutations
c.41A>G; p.K14R and c.340G>A; p.G114S. Schematic of alternative splice products of COX20 mRNA with primers and the 343 bp full-length and
224 bp DEXON2 mRNA products (B) cDNA products of RT-PCR of cellular mRNA with control cells expressing both the full-length and DEXON2.
Only the DEXON2 cDNA is expressed, there is no full-length cDNA. GAPDH cDNA expression is shown as the loading control. Bar graph shows
the normalized intensity of COX20/GAPDH signal in controls and subject. (C) Western blot indicates that subject cells had no identifiable COX20
expression in comparison to control cells. /b-actin expression is shown as the loading control. Bar graph shows the normalized intensity of
COX20/b-actin signal in controls and subject. Statistical analysis used two-tailed Student’s t-test. Values are expressed as means  standard
deviation (SD) for two independent experiments. ***P > 0.002.
158 ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
COX20 Presenting as Sensory Neuropathy and Ataxia M. G. Otero et al.
more importantly, the associated c.41A>G variant is
located at the 1 site of the intron 1 splice donor site
altering splicing of intron 1 in this allele. This alteration
explains why mRNA analysis revealed that little or no
full-length mRNA was produced, resulting in absent
COX20 expression. All four subjects had very similar pre-
sentations that included childhood hypotonia that pro-
gressed to hypertonia as they grew older. Other
prominent features included dysarthria, ataxia, areflexia,
and sensory neuropathy without motor neuropathy. The
three older subjects had developed dystonia in late child-
hood/early adolescence, while the youngest subject has
not developed this feature. Whether dystonia will be a
consistent feature of the disorder will require identifica-
tion of more affected subjects.
Sensory neuropathy is a prominent feature of COX20
deficiency, but is not a very common feature in many neu-
rogenetic disorders. When present, the use of this symp-
tom as a defining diagnostic feature can provide a more
limited differential diagnosis for a patient’s evaluation.
Friedreich ataxia is a more common disorder with sensory
neuropathy, while other less common disorders include
the later-onset disorder cerebellar ataxia with neuropathy
and bilateral vestibular areflexia syndrome (CANVAS) that
consists of vestibulopathy, ataxia, areflexia, and sensory
neuropathy.16 In addition, several of the spinocerebellar
ataxias (SCAs) also have ataxia associated with sensory
neuropathy, including SCA4 and SCA25 (and occasionally
SCA1, SCA8, and SCA27).17,18 Furthermore, sensory neu-
ropathy has been associated with other mitochondrial dis-
orders, including CPEO, MERRF, and MNGIE.19–21 POLG
mutations have also caused a mitochondrial disorders with
sensory neuropathy.19–21 In contrast to these disorders,
COX20 deficiency has a unique phenotype that can
include ataxia, areflexia, dysarthria, and dystonia. Previous
to this report, there have only been three reported COX20
deficiency cases, all of them associated with consanguinity
and homozygosity of the same variant. These nonconsan-
guineous subjects and their compound heterozygous
COX20 variants further confirm this unique phenotype’s
association with COX20 deficiency.
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Supporting Information
Additional supporting information may be found online in
the Supporting Information section at the end of the article.
Appendix S1. Additional methods and clinical information.
Figure S1. Neuroimaging. MRI of the brain and spinal cord
at 12 years. (A) MRI brain was within normal limits (B)
MRI of the spine was reported as her spinal cord “thinner
than normal, particularly in the thoracic region”.
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